Absolute Antibody growth & investment accelerates

How these providers of engineered antibodies have seen significant progress with 195% growth over the previous year.

Absolute Antibody Ltd is pleased to announce strongly accelerated growth in the last two quarters, with year-on-year sales growth at 195%.

The custom business, where Absolute Antibody provides service specific to customers’ requirements has seen an increase in large orders, including antibody humanisation and bispecific antibody projects.

The catalogue has grown into a broad range of over 2500 ‘off the shelf’ products. There is continued demand for defined and reliable antibody reagents in the pharmaceutical research and diagnostics sectors, as well as in academia.

To better support its customers, Absolute Antibody will expand its operation in both the UK and USA. Increased production and R&D will take place in the UK, to support increased demand for engineered antibodies and continue to develop new and innovative technologies. A full distribution business will be established in the USA to provide full time in-field support for all customers there.

"Our investment in a proprietary antibody manufacturing platform based on transient transfection ensured we could cater for expected significant increases in volume.” said Dr Nicholas Hutchings, CEO of Absolute Antibody, “Continued investment in people and processes allows us to support our customers’ individual needs whilst keeping pace with this high demand.”

New UK facilities in both Oxford and Redcar will go live over June and July, with USA expansion to follow.